S&CO Inc. boosted its holdings in Thermo Fisher Scientific Inc (NYSE:TMO) by 2.0% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 48,833 shares of the medical research company’s stock after buying an additional 940 shares during the period. Thermo Fisher Scientific accounts for approximately 1.1% of S&CO Inc.’s holdings, making the stock its 29th biggest position. S&CO Inc.’s holdings in Thermo Fisher Scientific were worth $8,520,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Waldron LP grew its position in shares of Thermo Fisher Scientific by 48.1% during the first quarter. Waldron LP now owns 4,455 shares of the medical research company’s stock valued at $661,000 after purchasing an additional 1,447 shares in the last quarter. Braun Stacey Associates Inc. grew its position in shares of Thermo Fisher Scientific by 0.6% during the first quarter. Braun Stacey Associates Inc. now owns 93,739 shares of the medical research company’s stock valued at $14,398,000 after purchasing an additional 525 shares in the last quarter. AMF Pensionsforsakring AB grew its position in shares of Thermo Fisher Scientific by 11.9% during the first quarter. AMF Pensionsforsakring AB now owns 537,308 shares of the medical research company’s stock valued at $82,531,000 after purchasing an additional 57,208 shares in the last quarter. BTC Capital Management Inc. grew its position in shares of Thermo Fisher Scientific by 19.3% during the first quarter. BTC Capital Management Inc. now owns 32,226 shares of the medical research company’s stock valued at $4,948,000 after purchasing an additional 5,217 shares in the last quarter. Finally, Wesbanco Bank Inc. grew its position in shares of Thermo Fisher Scientific by 1.9% during the first quarter. Wesbanco Bank Inc. now owns 48,569 shares of the medical research company’s stock valued at $7,460,000 after purchasing an additional 895 shares in the last quarter. Institutional investors and hedge funds own 83.52% of the company’s stock.

In other Thermo Fisher Scientific news, VP Peter E. Hornstra sold 3,894 shares of the business’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $185.18, for a total value of $721,090.92. Following the transaction, the vice president now directly owns 19,751 shares in the company, valued at approximately $3,657,490.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jim P. Manzi sold 1,000 shares of the business’s stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $175.20, for a total transaction of $175,200.00. Following the completion of the transaction, the director now owns 38,757 shares in the company, valued at $6,790,226.40. The disclosure for this sale can be found here. Insiders sold a total of 22,738 shares of company stock worth $4,021,512 over the last quarter. 0.49% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: “S&CO Inc. Has $8.52 Million Holdings in Thermo Fisher Scientific Inc (TMO)” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/09/12/sco-inc-has-8-52-million-holdings-in-thermo-fisher-scientific-inc-tmo.html.

Shares of Thermo Fisher Scientific Inc (NYSE:TMO) opened at 193.57 on Tuesday. The firm has a 50-day moving average of $178.20 and a 200 day moving average of $169.56. The company has a market cap of $75.52 billion, a P/E ratio of 33.72 and a beta of 1.05. Thermo Fisher Scientific Inc has a 52 week low of $139.07 and a 52 week high of $193.67.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.27 by $0.03. The company had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.92 billion. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. Thermo Fisher Scientific’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.03 EPS. Equities analysts expect that Thermo Fisher Scientific Inc will post $9.35 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be issued a $0.15 dividend. The ex-dividend date is Thursday, September 14th. This represents a $0.60 annualized dividend and a yield of 0.31%. Thermo Fisher Scientific’s payout ratio is 10.45%.

TMO has been the subject of a number of research analyst reports. Cleveland Research upgraded Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research report on Thursday, July 20th. Cowen and Company restated a “buy” rating and set a $200.00 price objective on shares of Thermo Fisher Scientific in a research report on Friday, September 1st. Bank of America Corporation restated a “buy” rating and set a $210.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Friday, July 21st. Zacks Investment Research lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Finally, Jefferies Group LLC restated a “hold” rating and set a $175.00 price objective on shares of Thermo Fisher Scientific in a research report on Wednesday, May 17th. One research analyst has rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $193.19.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.